NCT06197568View on ClinicalTrials.gov

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 1, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Postmenopausal Symptoms
Interventions
DRUG

Lasofoxifene Tartrate (AZU-101)

0.1 μg vaginal dose of AZU-101 weekly for 4 doses

DRUG

Lasofoxifene Tartrate (AZU-101)

0.5 μg vaginal dose of AZU-101 weekly for 4 doses

DRUG

Lasofoxifene Tartrate (AZU-101)

1 μg vaginal dose of AZU-101 weekly for 4 doses

DRUG

Lasofoxifene Tartrate (AZU-101)

0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses

DRUG

Lasofoxifene Tartrate (AZU-101)

0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses

Sponsors

Lead Sponsor

Azure Biotech Inc.
All Listed Sponsors
lead

Azure Biotech Inc.

INDUSTRY

NCT06197568 - Open-Label Study of Vaginal AZU-101 in Postmenopausal Women | Biotech Hunter | Biotech Hunter